KB-1309

Dupilumab

52700

Home » Dupilumab

Background of Dupilumab

Dupilumab, marketed under the brand name Dupixent, is a monoclonal antibody that functions by blocking interleukin 4 and interleukin 13. It is indicated for the management of allergic conditions such as eczema (atopic dermatitis), asthma, and nasal polyps, which often lead to chronic sinusitis. Additionally, Dupilumab is utilized in the treatment of eosinophilic esophagitis and prurigo nodularis.

Specifications

Catalog Number	KB-1309
Antibody Name	Dupilumab
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P/K447Del
Target	IL4Ra
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Buchheit KM, Sohail A, Hacker J, Maurer R, Gakpo D, Bensko JC, et al. (August 2022). "Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease". The Journal of Allergy and Clinical Immunology. 150 (2): 415–424.